1例盐酸厄洛替尼片致严重皮肤溃疡和角膜穿孔的药学监护

doi:10.19803/j.1672-8629.20211034

中国药物警戒 ›› 2023, Vol. 20 ›› Issue (2): 206-208.
DOI: 10.19803/j.1672-8629.20211034

1例盐酸厄洛替尼片致严重皮肤溃疡和角膜穿孔的药学监护

袁琪^1,2, 王颖娴^3Δ, 陈思颖^1*, 尤海生¹

¹西安交通大学第一附属医院药学部,陕西西安 710061;
²陕西省肿瘤医院药学部,陕西西安 710061;
³西安交通大学第一附属医院检验科,陕西西安 710061

收稿日期:2021-11-29 出版日期:2023-02-15 发布日期:2023-02-17
通讯作者: ^*陈思颖,女,博士,副研究员,肿瘤耐药及药动学的研究。E-mail: ychen0326@163.com
作者简介:袁琪,女,本科,主管药师,肿瘤临床药学。^Δ为并列第一作者。
基金资助:
陕西省重点研发计划一般项目（2020SF-210）

Pharmaceutical care for a case of severe skin ulcer and corneal perforation caused by erlotinib hydrochloride tablets

YUAN Qi^1,2, WANG Yingxian^3Δ, CHEN Siying^1*, YOU Haisheng¹

¹Department of Pharmacy, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an Shaanxi 710061, China;
²Department of Pharmacy, Shaanxi Provincial Cancer Hospital, Xi’an Shaanxi 710061, China;
³Department of Laboratory Medicine, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an Shaanxi 710061, China

Received:2021-11-29 Online:2023-02-15 Published:2023-02-17

摘要/Abstract

摘要： 目的对1例肺癌患者口服厄洛替尼发生不良反应的观察与随访,优化临床药师的用药监护和提高血药浓度监测（TDM）对患者的治疗作用。方法结合1例肺癌患者口服盐酸厄洛替尼片（特罗凯）治疗后同时发生皮肤溃疡和角膜穿孔的严重不良反应,临床药师采用循证药学和TDM对其进行药学监护。结果通过个体化用药调整,对发生的不良反应给予对症支持治疗,患者皮肤溃疡与角膜穿孔虽未能治愈,但疼痛明显缓解。结论临床药师在肿瘤患者用药治疗过程中,可利用临床药学专业协助临床医师对患者的个体化治疗提供药学服务,促进临床合理用药。

关键词: 厄洛替尼, 皮肤溃疡, 角膜穿孔, 药品不良反应, 过度暴露, 血药浓度

Abstract: Objective To optimize medication monitoring by clinical pharmacists and improve the role of therapeutic drug monitoring (TDM) via observation and follow-up of one case of adverse reactions caused by oral erlotinib. Methods Soon after one patient with lung cancer developed skin ulcer and corneal perforation following treatment with oral erlotinib, clinical pharmacists gave pharmaceutical care using evidence-based pharmacy and TDM. Results Through adjustment of the individualized medication regimen, symptomatic and supportive treatment of adverse reactions, the pain of the patient was significantly relieved, although her skin ulcer and corneal perforation were not cured. Conclusion In the course of medication for cancer patients, clinical pharmacists can use their expertise and knowledge to assist clinicians in providing individualized pharmaceutical care for patients, and contribute to rational clinical use of drugs.

Key words: erlotinib, skin ulcers, corneal perforation, adverse drug reaction, overexposure, blood concentration

中图分类号:

袁琪, 王颖娴, 陈思颖, 尤海生. 1例盐酸厄洛替尼片致严重皮肤溃疡和角膜穿孔的药学监护[J]. 中国药物警戒, 2023, 20(2): 206-208.

YUAN Qi, WANG Yingxian, CHEN Siying, YOU Haisheng. Pharmaceutical care for a case of severe skin ulcer and corneal perforation caused by erlotinib hydrochloride tablets[J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 206-208.

参考文献

[1] PETIT AM, RAK J, HUNG MC, et al.Neutralizing antibodies againstepidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy ofsolid tumors[J]. Am J Pathol, 1997, 151(6): 1523-1530.
[2] ETTINGER DS, WOOD DE, AISNER DL, et al.NCCN guidelinesinsights: non-small cell lung cancer, version 2.2021[J]. J Natl Compr Canc Netw, 2021, 19(3): 254-266.
[3] TAMURA M, TAKAI Y, NAKAMURA S, et al.A case report of pseudo-exfoliation syndrome with prolonged corneal epithelial regeneration because of erlotinib-induced unilateral corneal ulcer and anterior uveitis[J]. Acta Ophthalmol, 2020, 98(8): e1055-e1056.
[4] BRADEN RL, ANADKAT MJ.EGFR inhibitor-induced skinreactions: differentiating acneiform rash from superimposed bacterial infections[J]. Support Care Cancer, 2016, 24(9): 3943-3950.
[5] LACOUTURE ME.Mechanisms of cutaneous toxicities to EGFRinhibitors[J]. Nat Rev Cancer, 2006, 6(10): 803-812.
[6] OWCZAREK W, SŁOWIŃSKA M, LESIAK A, et al. The incidenceand management of cutaneous adverse events of the epidermal growth factor receptor inhibitors[J]. Postepy Dermatol Alergol, 2017, 34(5): 418-428.
[7] BORKAR DS, LACOUTURE ME, BASTI S.Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review[J]. Support Care Cancer, 2013, 21(4): 1167-1174.
[8] CHOI HD, CHANG MJ.Eye, hepatobiliary, and renal disorders of erlotinib in patients with non-small-cell lung cancer: a meta- analysis[J]. PLoS One, 2020, 15(7): e0234818.
[9] ENDO-TSUKUDE C, SASAKI JI, SAEKI S, et al.Population Pharmacokinetics and adverse events of erlotinib in japanese patients with non-small-cell lung cancer: impact of genetic polymorphisms in metabolizing enzymes and transporters[J]. Biol Pharm Bull, 2018, 41(1): 47-56.
[10] MUELLER-SCHOELL A, GROENLAND SL, SCHERF-CLAVELO, et al.Therapeutic drug monitoring of oral targeted antineoplastic drugs published correction appears in Eur J Clin Pharmacol[J]. Eur J Clin Pharmacol, 2021, 77(4): 441-464.
[11] LU JF, EPPLER SM, WOLF J, et al.Clinical pharmacokineticsof erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer[J]. Clin Pharmacol Ther, 2006, 80(2): 136-145.
[12] BIGOT F, BOUDOU-ROUQUETTE P, ARRONDEAU J, et al.Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old[J]. Investigational New Drugs: The Journal of New Anticancer Agents, 2017, 35(2): 242-246.
[13] NANNEY LB, MAGID M, STOSCHECK CM, et al.Comparison of epidermal growth factor binding and receptor distribution in normal human epidermis and epidermal appendages[J]. J Invest Dermatol, 1984, 83(5): 385-393.
[14] CHARALAMBOUS A.Living with the effects of cutaneous toxicities induced by treatment[J]. Asia Pac J Oncol Nurs, 2017 , 4(3): 220-223.
[15] LIU Z, CARVAJAL M, CARRAWAY CA, et al.Expression ofthe receptor tyrosine kinases, epidermal growth factor receptor, ErbB2, and ErbB3, in humanocularsurfaceepithelia[J]. Cornea, 2001, 20(1): 81-85.
[16] NA NNEY LB, STOSCHECK CM, KING LE JR, et al.Immunolocalization of epidermal growth factor receptors in normal developing human skin[J]. J Invest Dermatol, 1990, 94(6): 742-748.
[17] CIESKE JD, TAKAHASHI H, HUTCHEON AE, et al.Activation of epidermal growth factor receptor during corneal epithelial migration[J]. Invest Ophthalmol Vis Sci, 2000, 41(6): 1346-1355.
[18] PETERSON JL, CERESA BP.Epidermal growth factor receptor expression in the corneal epithelium[J]. Cells, 2021, 10(9): 2409.

1例盐酸厄洛替尼片致严重皮肤溃疡和角膜穿孔的药学监护

Pharmaceutical care for a case of severe skin ulcer and corneal perforation caused by erlotinib hydrochloride tablets

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[3]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[4]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[5]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[6]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[7]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[8]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[9]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[10]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[11]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[12]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.
[13]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[14]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.
[15]	刘文东, 崔欢欢, 王晓晗, 苏娴, 王海学. 我国儿童用药临床试验期间药物警戒监管体系现状及思考[J]. 中国药物警戒, 2023, 20(9): 1002-1006.